ChemoCentryx, Inc. (NASDAQ:CCXI) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Monday.

According to Zacks, “ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. “

Other equities analysts also recently issued reports about the stock. ValuEngine downgraded shares of ChemoCentryx from a “hold” rating to a “sell” rating in a research note on Friday. BidaskClub downgraded shares of ChemoCentryx from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 10th. Finally, Cowen and Company reissued a “hold” rating on shares of ChemoCentryx in a research note on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the stock. ChemoCentryx currently has a consensus rating of “Hold” and a consensus price target of $8.25.

Shares of ChemoCentryx (NASDAQ CCXI) traded up $0.08 during trading on Monday, hitting $7.49. 59,000 shares of the company traded hands, compared to its average volume of 141,167. ChemoCentryx has a 12-month low of $6.13 and a 12-month high of $10.80.

ChemoCentryx (NASDAQ:CCXI) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.13. analysts forecast that ChemoCentryx will post -0.67 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/13/zacks-investment-research-lowers-chemocentryx-inc-ccxi-to-hold.html.

Institutional investors have recently modified their holdings of the company. Bank of Montreal Can acquired a new position in shares of ChemoCentryx in the 2nd quarter valued at $102,000. JPMorgan Chase & Co. purchased a new position in ChemoCentryx during the 2nd quarter worth $104,000. Voya Investment Management LLC raised its position in ChemoCentryx by 22.8% during the 2nd quarter. Voya Investment Management LLC now owns 15,984 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 2,965 shares during the last quarter. Trexquant Investment LP raised its position in ChemoCentryx by 81.1% during the 2nd quarter. Trexquant Investment LP now owns 18,600 shares of the biopharmaceutical company’s stock worth $174,000 after buying an additional 8,327 shares during the last quarter. Finally, State of Wisconsin Investment Board purchased a new position in ChemoCentryx during the 2nd quarter worth $178,000. Institutional investors and hedge funds own 49.15% of the company’s stock.

ChemoCentryx Company Profile

ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.

Get a free copy of the Zacks research report on ChemoCentryx (CCXI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.